fda stopping semaglutide U.S. finds no evidence yet linking weight-loss drugs to suicidal thoughts FDA stops sale of cheaper

A new study reports that GLP-1 medications may provide benefits to cognitive and behavioral health, including lowered addiction risk

Psychopharmacological research has not produced substantial innovations, nor have there been convincing biological explanations of mental states in health and disease

Currently, completion of ongoing kidneyspecific outcomes trials (Table 1) and regulatory approval are needed for widespread use of GLP1 RAs in CKD

Always check if a product is registered with the FDA by using the FDA Verification Portal feature accessible at All Local Government Units (LGUs) and Law Enforcement Agencies (LEAs) are requested to ensure that this product is not sold or made available in their localities or areas of jurisdiction